Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA GlobeNewswire - Tue Oct 8, 6:30AM CDT

IONS : 38.63 (+0.49%)
BIIB : 191.56 (+1.69%)
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag Zacks Investment Research - Wed Oct 2, 9:16AM CDT

Ionis Pharmaceuticals, Inc. IONS announced that the FDA has granted a Fast Track designation to its investigational RNA-targeted therapy zilganersen for treating Alexander disease (AxD), an ultra-rare...

KRYS : 179.58 (+0.49%)
FULC : 3.57 (+2.59%)
IONS : 38.63 (+0.49%)
ANIP : 58.50 (+2.38%)
Ionis Pharmaceuticals: Q2 Earnings Snapshot AP - Thu Aug 1, 6:32AM CDT

Ionis Pharmaceuticals: Q2 Earnings Snapshot

IONS : 38.63 (+0.49%)
Ionis Pharmaceuticals: Q1 Earnings Snapshot AP - Tue May 7, 6:07AM CDT

Ionis Pharmaceuticals: Q1 Earnings Snapshot

IONS : 38.63 (+0.49%)
Ionis Pharmaceuticals: Q4 Earnings Snapshot AP - Wed Feb 21, 6:06AM CST

Ionis Pharmaceuticals: Q4 Earnings Snapshot

IONS : 38.63 (+0.49%)
Wall Street - shutterstock_2148457839
Markets Today: Stock Index Futures Add to Record Highs on U.S. Economic Optimism Barchart - Mon Jan 22, 7:53AM CST

Morning Markets March E-Mini S&P 500 futures (ESH24 ) are up +0.35%, and March Nasdaq 100 E-Mini futures (NQH24 ) are up +0.57%, both at new all-time nearest-futures highs. Stock index futures this morning...

ESZ24 : 5,912.25 (+0.07%)
NQZ24 : 20,619.00 (unch)
SMCI : 47.39 (-0.86%)
ZS : 196.74 (-0.77%)
M : 15.38 (-2.53%)
S : 26.41 (+2.72%)
IONS : 38.63 (+0.49%)
NS : 21.96 (-1.83%)
NET : 93.75 (+0.30%)
ADM : 57.91 (-0.10%)
BA : 148.99 (-1.34%)
RILY : 5.42 (+23.46%)
Ionis Pharmaceuticals: Q3 Earnings Snapshot AP - Thu Nov 2, 2023

Ionis Pharmaceuticals: Q3 Earnings Snapshot

IONS : 38.63 (+0.49%)
Ionis to hold third quarter 2023 financial results webcast PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, November 2nd at 11:30 a.m. Eastern...

IONS : 38.63 (+0.49%)
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization PR Newswire - Wed Oct 4, 2023

With experienced commercial team in place, Ionis poised to independently bring steady cadence of potentially transformational RNA-targeted medicines to...

IONS : 38.63 (+0.49%)
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit PR Newswire - Thu Sep 28, 2023

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that The Journal of the American Medical Association (JAMA) published positive...

IONS : 38.63 (+0.49%)

Barchart Exclusives

Grab This Warren Buffett Dividend Stock While It's Cheap Barchart - Mon Oct 14, 6:30PM CDT
Warren Buffett has taken a significant stake in Occidental Petroleum (OXY), a dividend-paying energy stock trading at a discount, with attractive valuation metrics and a steady dividend yield. OXY's strategic moves, debt reduction efforts, and expansion in the Permian Basin make it a potentially lucrative investment opportunity. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot